Hospital Motto

Holding a benevolent heart, delivering high-quality medical care, seeking truth, pursuing innovation

Overview
Hospital History
Leadership
Awards & Honors
Newsroom
Location & Maps
Contact Us

Hospital Motto

Holding a benevolent heart, delivering high-quality medical care, seeking truth, pursuing innovation

Departments & Centers
Find a Doctor
How to schedule my visit
Insurance Partner & Charge List
Women's Healthcare

Hospital Motto

Holding a benevolent heart, delivering high-quality medical care, seeking truth, pursuing innovation

Overview
News And Information
Notice Announcement
Education Management
Overseas Exchanges
Teaching Staff

Hospital Motto

Holding a benevolent heart, delivering high-quality medical care, seeking truth, pursuing innovation

Overview
Invetigators
Research Team
Institutes
Paper Chase
Patents
Clinical Trials

Hospital Motto

Holding a benevolent heart, delivering high-quality medical care, seeking truth, pursuing innovation

Overview
Cooperative Partners
Guest Professors
Contact Us

Sima Ni

Title:

Associate chief physician, Ph.D.

Bio:

Education:

2007Ph.D. Tongji Medical College, Huazhong University of Science and Technology

2004Master of MedicineJiangxi Medical College

2000Bachelor of Medicine Tongji Medical University


Expertise: 

Gynecologic oncology, Recurrent abortion


Research Interests:

Gynecologic oncology


Research Narrative:

The mortality rate of ovarian cancer ranks first among female reproductive tract malignant tumors, which seriously threatens women's life and health. The molecular mechanism of cisplatin and paclitaxel resistance in ovarian cancer is still uncertain. As a visiting scholar, I have done research on high-throughput drug screening for ovarian cancer in the National Institutes of Health in the United States for nearly two years. Drug repurposing screening reveals novel targets and drug combinations can combat cisplatin-resistant ovarian cancer. We use drug repurposing screening in cisplatin-resistant ovarian cancer cell using FDA-approved libraries and MIPE libraries to search for possible drugs sensitive to cisplatin, and then use the screened drugs to reverse explore and construct the possible mechanism of platinum resistance in ovarian


Publication:

[1]Sima N, Sun W, Gorshkov K, Shen M, Huang W, Zhu W, Xie X, Zheng W, Cheng X. Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Transl Oncol. 2018 Aug;11(4):1053-1064.

[2]Sima N, Li R, Huang W, Xu M, Beers J, Zou J, Titus S, Ottinger EA, Marugan JJ, Xie X, Zheng W. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis. 2018 Apr 10;13(1):54.

[3]Sima N, Cheng X, Ye F, Ma D, Xie X, Lu W. The Overexpression of Scaffolding Protein NEDD9 Promotes Migration and Invasion in Cervical Cancer via Tyrosine Phosphorylated FAK and SRC. PLoS One 2013; 8(9): e74594.

[4]Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, Xu G, Meng L, Lu Y, Wang S, Ma D. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 2008; 13(2): 273-81.

[5]Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou J, Xu G, Meng L, Lu Y, Ma D. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 2007; 106(2): 299-304.


E-Mail:

simani@163.com


Purpose

Providing high-quality healthcare for women and children

LEARN MORE